Mice with severe combined immunodeficiency were inoculated intraperitoneally with 50x 106 human tonsillar mononuclear cells (hu-TMCs) from EpsteinBarr virus (EBV) antibody seropositive or seronegative human subjects. Between 5 and 11 weeks later, 29.4% (10/34) of mice injected with hu-TMCs from EBV seropositive donors, but none of 34 animals receiving hu-TMCs from EBV seronegative donors, developed intraabdominal and/or intrathoracic tumours (P, 0.002). By means of in situ hybridization using alpha satellite DNA from human chromosome 17, all tumours produced after cell transfer from EBV seropositive donors were identified to be of human origin. Histologically the tumours resembled large cell lymphomas; the EBV genome was detected by in situ hybridization and EBV nuclear antigen by immunofluorescence in these tumours. The tumours were polyor oligoclonal, and stained for human IgG and IgM, and less frequently IgA and IgD. Serum levels of human immunoglobulin in animals developing human tumours were significantly higher than in reconstituted mice without tumours and the sera exhibited polyoligo-or monoclonality in immunoelectrophoresis. Human interleukin 6 was detected in the serum of six of 10 animals with human lymphomas, but not in any animals without human lymphoma.
Introduction
Epstein-Barr virus (EBV) is a lymphotropic human herpesvirus. Primary infection with EBV occurs in childhood or adolescence via the oropharynx. The course of this infection is usually benign, and may be clinically silent, manifest as non-specific signs and symptoms, or exhibit the classical picture of infectious mononucleosis (Brown, 1987) . Despite the generation of an immune response against EBV, the agent is not cleared from the body; the virus is intermittently reactivated and shed via the oropharynx throughout life . Primary infection with or reactivation of EBV, however, can result in severe disease in immunocompromised individuals. Children with congenital primary immunodeficiences (Virelizier et al., 1978; Purtilo et al., 1982) , immunosuppressed allograft organ and bone marrow recipients (Hanto et al., 1982; Cleary et al., 1984; Ho et aL, 1985; Shapiro et al., 1988; Zutter et at., 1988; Swinnen et al., 1990) , and patients immunocompromised by human immunodeficiency virus are especially susceptible to EBV-associated malignant and often fatal lymphoproliferation Birx et al., 1986; Hamilton-Dutoit et al., 1991) . Furthermore, EBV has been strongly linked to other malignancies, including Burkitt's lymphoma, Hodgkin's and non-Hodgkin's lymphoma, T cell neoplasia, nasopharyngeal carcinoma and hairy leukoplakia (de Th6 et al., 1978; Greenspan et al., 1985; Jones et al., 1988; Young et al., 1988; Harabuchi et al., 1990; Pallesen et al., 1991) . Information about the pathogenic events involved in these malignancies is limited because the natural host range of EBV is restricted to man.
Recently, the adoptive transfer of human cells into mice with severe combined immunodeficiency (SCID) has provided a novel tool for the study of human immunobiology in vivo (McCune et al., 1988; Mosier et al., 1988) . Two approaches have been demonstrated to result in successful engraftment of human cells into SCID mice: the surgical implantation of human foetal tissue (McCune et al., 1988) or post-natal thymus (Barry et aL, 1991) and the intraperitoneal (i.p.) transfer of peripheral blood leukocytes from adults (hu-PBL-SCID mouse) (Mosier et al., 1988; Chen et al., 1991) or tonsillar mononuclear cells (hu-TMCs; hu-TMC-SCID mouse) from children or adolescents (Nadal et al., 1991a) .
The present study was undertaken for the following reasons, to examine the histological, immunological and (Okamoto et al., 1988) . The purity of the hu-TMCs in single-cell suspensions was
>95~
Mice. C.B-17 scid/scid mice (Bosma et al., 1983) were originally obtained from the Fox Chase Cancer Institute, Philadelphia, Pa., U.S.A., bred in our own animal unit and maintained in microisolator cages (Labproducts). Food, water and bedding were sterilized. Only 4-to 8-week-old animals with serum levels of murine immunoglobulin (Ig) <5 ktg/ml ('nonleaky ~) were used for adoptive cell transfer.
Study protocol. The characteristics of the cell donors and the groups of recipient mice are summarized in Table 1 . Group 1 consisted of 34 animals which received cells from 17 anti-EBV virus capsid antigen (VCA) IgG seropositive donors aged 3 to 20 years (mean 10.2); group 2 included 34 animals which received cells from 17 anti-EBV VCA IgG seronegative individuals aged 3 to 19 years (mean 7.59). Each animal was injected i.p. with 50 x 106 hu-TMCs. The animals were bled every 2 weeks and then killed. The mice were killed at regular intervals for 5 to 11 weeks after cell transfer.
Antobodies to EBV. Sera from hu-TMC donors and from hu-TMC-SCID mice were investigated for human antibodies to EBV-encoded 
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* SCID mice were reconstituted with 50 x l06 hu-TMCs i.p. and killed at regular intervals for 5 to 11 weeks after cell transfer.
~" Pos t Positive, + ; negative, -. :~ P, 0-002.
VCA by a standard indirect immunofluorescence test (Henle et al., 1974) (Zeus) . No cross-reactivity was detected in control experiments using sera from non-reconstituted SCID mice or murine IgG as test samples.
Histopathology and immunohistochemistry. Tumour tissue was cut into pieces and fixed in 10~ formaldehyde, embedded in paraffin wax, cut into 5 rtm sections, and stained with haematoxylin and eosin. Aliquots of tumour tissue were embedded in optimal cutting compound (Miles Laboratories), snap frozen in liquid nitrogen and stored at -70°C until cryosections of 6 p.m were cut using a Cryocut (Cambridge Instruments) at -20 °C. The sections were subjected to histological or immunohistological analysis, respectively. Frozen sections were also used for hybridization studies.
Hybridization for human chromosome. To identify tumour cells as being of human origin, frozen sections were subjected to in situ hybridization (Pinkel et al., 1986) with the human alpha satellite DNA from chromosome 17 (D17Z1, p17H8) (Oncor), which is a major fragment of 2.7 kb after digestion with EcoRI (Waye & Willard, 1986) .
After fixation of the tissue with acetone/chloroform (1 : 1) at 4 °C for 10 min, the cells were permeabilized by treatment with Triton (0.5~) and NP40 (0.5 ~) at 90 °C for 15 min. For each section, 1.5 ktl biotin-labelled probe (10 ng/ml) mixed with 30 ktl Hybrisol VI (Oncor) and denatured at 70 °C for 5 min was hybridized for 20 h at 55 °C in a humidified chamber. Repeated washes in formamide (Sigma) diluted to 65~ in 2 x sodium chloride/sodium citrate at 43 °C for 20 min and in 2 x sodium chloride/sodium citrate at 37 °C were followed by two blocking steps. To saturate any avidin present, the sections were incubated with anti-avidin antibodies (Oncor). Bound probe was detected by incubation of the sections with fluorescein isothiocyanate (FITC)-labelled avidin at 37 °C for 20 min. Finally, the slides were washed, counterstained with Evans blue and analysed by fluorescence microscopy. In control experiments, human alpha satellite DNA from chromosome 17 did not hybridize with splenocytes from BALB/c mice or tissue sections from non-reconstituted SCID mice.
Hybridization analysis to detect the EBV genome. Acetone/chloroform-fixed frozen sections of tumours were hybridized with a 3 kb sequence from the BamHI V (internal repeat 1) region of the EBV genome (Dambaugh et al., 1980) cloned into pBR322 (ENZO Diagnostics) for 10 min on a 92 °C heating block, and for 20 min at room temperature. Binding of biotinylated probe was detected using avidin-horseradish peroxidase and amino-ethyl-carbazole as substrate. The slides were counterstained with methyl green and analysed by light microscopy.
Immunofluorescence analysis to detect human lg and lymphoid cell markers. Frozen sections, placed onto poly-L-lysine (Sigma)-coated slides, were stained for human Ig light chains using rhodamine-labelled goat anti-human x chain or FITC-conjugated goat anti-2 chain antibodies (Cappel) and for human Ig using FITC-labelled goat antihuman IgG, IgA or IgM (Tago), shown not to cross-react with lymphocytes from BALB/c mice or tissue from non-reconstituted SCID mice. The antisera were incubated for 45 min at 37 °C in a humidified chamber.
The following murine monoclonal antibodies (MAbs) were used for additional immunophenotyping of the tumour cells in a two-step assay: anti-CD19 (Leu 12), anti-CD20 (Leu 16), anti-CD3 (Leu 4), anti-CD4 (Leu 3) and anti-CD8 (Leu 2) (all from Becton Dickinson). These primary MAbs were incubated for 2 h at 37 °C. FITC-labelled goat anti-mouse IgG (Sigma) served as the second antibody, which was incubated for 1 h at 37 °C. Evans blue was used for counterstaining of most preparations.
Immunofluorescence assay for detection of EBV nuclear antigen (EBNA).
To detect EBNA in the nuclei of the tumour cells, frozen sections were incubated with a human serum of known anti-EBNA antibody titre for 45 min at 37 °C, washed repeatedly with PBS and incubated with FITC-labelled goat anti-human Ig (Tago). Staining of the nuclei was compared to the staining in sections incubated with an anti-EBNA antibody-negative human serum or with conjugate only.
Human interleukin 6 (1L-6) in sera of hu-TMC-SCID mice. Final sera from hu-TMC-SCID mice and control animals were tested for the presence of human IL-6 by a sandwich ELISA using a mouse antihuman IL-6 MAb for capture and a horseradish peroxidase-conjugated rabbit polyclonal anti-human IL-6 antiserum (R&D Systems). Briefly, 200 gl of mouse serum diluted 1 : 10 in a cytokine-free animal serum as provided by the manufacturers was incubated for 2 h at room temperature in a well. The samples were run in triplicate. After a washing step, the conjugate was incubated for 2 h at room temperature, washed again, and then tetramethylbenzidine and HzO z were used as chromogens. The colour reaction was stopped with 1 M-HzSO 4 after 20 min and the absorbance at 450 nm determined. The average values were plotted against a standard curve constructed by testing serial dilutions of recombinant human IL-6 (R&D Systems). No crossreactivity of the IL-6 ELISA with other cytokines [granulocyte/macrophage colony stimulating factor (GM-CSF), G-CSF, M-CSF, IL-3, IL-2, IL-4, tumour necrosis factor or erythropoietin] was observed, and the method was sensitive to concentrations as low as 3.5 pg/ml. The crossreactivity with murine IL-6 was found to be < 0.1%
Detection of murine Ig. Screening of the mice for murine Ig production ('leakiness') was done by ELISA. Briefly, microtitre plates (Costar) were coated with goat anti-mouse Ig (Sigma) and free binding sites were blocked with PBS containing 1 ~ bovine serum albumin. Duplicate samples of mouse serum diluted 1:5000 in PBS, 0-05% Tween 20 (Sigma) and of standards for murine Ig were incubated for 2 h at room temperature, and bound murine Ig was detected by adding horseradish-conjugated goat anti-mouse Ig (Sigma) for 1 h. Bound enzyme activity was detected using o-phenylenediamine substrate (Sigma) and the absorbance at 429 nm was determined using an automated multiscan ELISA reader (Titertek Multiskan MCC; Flow Laboratories).
Serum human Igs.
For the detection of human Ig in the sera of hu-TMC-SCID mice, a sandwich ELISA was performed using rabbit polyclonal anti-human ~,, c~ and # heavy chain antisera (Dakopatts). The second antibody was labelled with horseradish peroxidase. Serial dilutions of mouse serum with PBS, 0.1~ bovine serum albumin, starting at 1:20, were incubated for 1 h at 37 °C. After repeated washing with PBS, the second antibody was incubated also for 1 h at 37 °C. Colour was developed using o-phenylenediamine and the absorbance at 492 nm was determined. The Ig values were calculated by interpolation of the linear standard curve constructed with serial dilutions of known concentrations of pure human Ig (Dakopatts) included in each plate.
Serum protein electrophoresis and immunoelectrophoresis (IEP).
Electrophoresis of mouse serum protein was done according to standard procedures using Titan III cellulose acetate plates (Helena Diagnostics), stained with Ponceau S (Sigma) and analysed by densitometry.
IEP was performed using agarose gel medium overlaid on a plastic film, and antisera to total human Ig and the heavy and light chains ~,, cq p, K and 2 (Kallestad Diagnostics). Mouse serum (8 gl) was run for 1 h at 60 mA and subsequently incubated with the antisera for 24 h. After repeated washing the gels were stained with Ponceau S.
Statistical analysis.
Values are expressed as mean +_ S.E.M. unless stated otherwise. Chi-square with Yate's correction and the MannWhitney U test were used for statistical analysis (Kramer, 1988) . Probability values < 0.05 were regarded as significant.
Results

Histological and immunopathological characteristics of tumours in reconstituted SCID mice.
Between 5 and 11 weeks (average 7.3) after i.p. injection of hu-TMC, tumours were seen in 10 of 34 mice (group 1 in Table 1 ), but in none of the mice receiving hu-TMCs from EBV seronegative donors (group 2 mice in Table 1 ; 29.4% against 0%; P, 0-002). Cells from three of the 17 EBV antibody-seropositive donors produced neoplasms in all reconstituted mice (n = 4). Cells from another six of these 17 donors, however, induced tumours in some but not all of the reconstituted SCID mice. None of the mice injected with cells from the remaining eight EBV antibody-seropositive donors developed tumours. Within donors seropositive for anti-EBV VCA IgG, there was no significant difference in age or anti-EBV VCA IgG titre between individuals relative to the development of tumours during the observation period.
The characteristics of the tumours observed after the transfer of EBV antibody-seropositive donor cells to the 10 animals are presented in Table 2 . In eight of the 10 mice the tumours were localized in the abdomen. In two of these eight mice the tumour showed infiltration of the liver (mice no. 2 and 6, Table 2), and in one mouse a second tumour was found in the thorax (mouse no. 7, Table 2); two mice had tumours in the thorax only (mice no. 1 and 8). Virtually all tumours exhibited a mixture of lymphoplasmacytoid, lymphocytic, immunoblastic and plasmacytic cells (Fig. 1 a) . All 10 tumours were classified (Stansfield et al., 1988) as diffuse large cell lymphomas of the immunoblastic plasmacytoid type (Table 2) and resembled the tumours seen in EBV-associated lymphoproliferation in immunocompromised patients.
Using the alpha satellite DNA from human chromosome 17 for in situ hybridization, all the tumours in hu-TMC-SCID mice were identified to be of human origin (Table 2 and Fig. 1 b) . Using this technique, we also analysed two tumours seen in SCID mice not reconstituted with human cells as controls. Neither tumour contained human chromosomes and both stained with the murine T cell marker, Thy 1.2 (data not shown).
By means of in situ hybridization, cells containing the EBV sequence from the BamHI V region (internal repeat 1) were found within all these tumours at a frequency of up to 5% (Table 2 and Fig. lc) . EBNA was detected by immunofluorescence using a human serum with known antibody titre to EBNA in 20 to 90% of cells (Table 2 and Fig. 1 d) .
To examine the clonality of the tumours, cryostat sections of the tumours were stained for the human Ig light chains x and 2. None of the tumours was found to be monoclonal; six tumours were either polyclonal or oligoclonal (mice no. 3, 5, 6 and 8 to 10; other tumours stained predominantly for x light chain (mice no. 1, 4, 7; Table 2 ) and one for 2 light chain (mouse no. 2; Table 2 ). All tumours showed cells positive for surface or cytoplasmic human IgG and/or IgM (Table  2) , ranging from 10~ to 80~ of cells positive for IgG, and from 20~ to 70~ positive for IgM. Seven tumours did also stain for surface or cytoplasmic human IgA (mice no. 1, 3 to 6, 8 and 10; Table 2 ) and five tumours for surface IgD (mice no. 1, 2, 4, 6 and 7; Table 2 ) (a maximum of 15 ~o of the ceils). Surface IgD-positive cells were seen in areas which contained cells positive for IgM. All tumours stained quite extensively for CD 19 and CD20. Little staining was seen for cells belonging to the T cell lineage (Table 2) .
Functional characteristics of tumours in reconstituted SCID mice
Protein electrophoresis of sera from animals with human tumours revealed the presence of a broad-based IgG peak, which was less marked in hu-TMC-SCID mice without tumours and was not observed at all in nonreconstituted SCID mice (data not shown). The patterns for albumin and ~1-, ~2-and/%globulins were similar in tumour-bearing and non-tumour-bearing mice, except for two hu-TMC-SCID mice with tumours involving the liver (mice no. 2 and 6). These two mice showed decreased amounts of albumin and increased amounts of ~2 globulin (data not shown).
The results of the IEP analysis for human Ig in SCID mice sera are presented in Table 3 . Of the 10 hu-TMC-SCID mice with lymphomas, eight had oligoclonal or monoclonal patterns for K and/or 2 light chains. With respect to isotype, oligoclonality or monoclonality for IgG was observed in six animals and for IgM in five mice. The pattern of clonality for IgA was polyclonal in five mice and could not be assessed in the remaining five mice owing to low serum levels. Animals without tumours showed only polyclonal patterns. No human Ig chains were detected in non-reconstituted control SCID mice (Table 3) .
Hu-TMC-SCID mice with tumours showed significantly higher serum levels of IgG, IgA and IgM than non-tumour-bearing hu-TMC-SCID mice (data not shown). Since this difference might be donor-related, we compared the serum Ig levels in tumour-bearing mice (n = 6) with those in non-tumour-bearing animals (n = 6) reconstituted with hu-TMC from the same donors. The results are presented in Fig. 2 . Tumour-bearing mice exhibited higher mean levels of IgG, IgA and IgM than tumour-free mice. The differences were statistically significant (P < 0-05) for IgG after weeks 5 to 6, and for IgA and IgM after week 1. 
P P P P P n, 10 P P P P P n, 3 N N N N N * P, Polyclonal; O, oligoclonal; M, monoclonal; NA, no assessment possible; N, negative.
Owing to the high Ig levels seen in animals with h u m a n lymphomas, we tested the sera of these animals a n d those of animals without tumours for the presence of IL-6. Of 10 a n i m a l s with h u m a n lymphomas, six exhibited IL-6 reactivity ranging from 64 to 1050 pg/ml (mice no. 2, 3, 5 to 7 and 10; Fig. 3 ). In contrast, IL-6 was not detected in the sera of 10 other h u -T M C -S C I D mice (including the six animals injected with h u -T M C s which produced tumours in other S C I D mice), of four nonreconstituted S C I D mice and of two non-reconstituted S C I D mice with m u r i n e T cell lymphomas. H u -T M C -S C I D mice with h u m a n IL-6 activity in their serum exhibited higher m e a n serum levels of h u m a n IgG, IgA and IgM t h a n mice with no detectable IL-6 (IgG: 2533.3 + 985-4 ~tg/ml versus 775-0 + 356-8 txg/ml; IgA: 4 5 . 6 + 1 9 -2 ~tg/ml versus 1 6 . 4 + 7 . 3 ~tg/ml; I g M : 719.1 + 607-4 ~tg/ml versus 239.1 + 162.6 txg/ml).
Antibody response to late viral antigens in hu-TMC-SCID mice
The results of the longitudinal analysis of the production of h u m a n a n t i b o d y against EBV V C A in reconstituted •
Human Murine Fig. 3 . Concentrations of human IL-6 in the serum of different groups of SCID mice. Hu-TMC-SCID mice were reconstituted with 50 x 106 hu-TMCs. Hu-TMC-SCID mice with human tumours (n, 10), hu-TMC-SCID mice with no tumours (n, 10; including six mice which received hu-TMCs which produced tumours in other SCID mice), nonreconstituted SCID mice without turnouts (n, 4) and non-reconstituted SCID mice with murine tumours (n, 2) were tested. Human IL-6 levels were measured by ELISA in the final sera of the animals. Table 4 . Anti-VCA IgG antibodies were detected in eight of the 10 animals. The titres increased with time after cell transfer and ranged from 1 : 10 to 1 : 1280. The highest titres were recorded in animals showing anti-EBV VCA IgG antibodies 2 weeks post-hu-TMC transfer. Of the eight mice with IgG antibodies to EBV VCA, six had titres equal to or higher than the cell donors. Furthermore, IgM antibodies against EBV VCA were detected in three of the 10 final sera (Table 4) .
Discussion
The observations summarized in this report suggest that hu-TMCs from EBV antibody-positive children and young adults give rise to large cell lymphomas of human origin when transferred into SCID mice. Histologically, the lymphomas appear to be similar to those observed in immunosuppressed organ allograft recipients. The tumours demonstrated poly-or oligoclonality, and harboured cells containing the EBV genome and EBNA. All animals which developed lymphomas of human origin exhibited high serum levels of different human Ig isotypes. Most of the tumour-bearing hu-TMC-SCID mice produced human anti-EBV VCA antibodies and had detectable levels of human IL-6 in the serum.
Using i.p. cell transfer, the engraftment of human peripheral blood lymphocytes (hu-PBLs) from donors suffering from autoimmune disorders such as primary biliary cirrhosis (Krams et al., 1989) , systemic lupus erythematosus (Duchosal et al., 1990) and rheumatoid arthritis (Tighe et al., 1990) has resulted in the production of human autoantibodies within the hu-PBL-SCID mouse and lesions in murine organs resembling those seen in the human donors. Moreover, transferred human cells have been shown to express immune reactivity upon challenge with bacterial (Mosier et al., 1988) or viral antigens (Nadal et al., 1991b) . The transfer of human lymphoid cells, however, can also result in apparently unrestricted lymphoproliferation. In the original description of the construction of the hu-PBL-SCID mouse chimeras, Mosier et al. (1988) reported that some animals receiving cells from EBV antibody-seropositive donors as xenografts develop human lymphomas. More recently, this observation has been extended by other investigators who have reported lymphomas of human type in SCID mice after i.p. transfer of hu-PBLs from EBV-seropositive donors (Bankert et al., 1989; Rowe et al., 1991) or by transfection of human lymphoid cells from EBV antibody-seronegative donors with EBV within the SCID mouse (Cannon et al., 1990; Okano et al., 1990; Purtilo et al., 1991) .
Tonsils and other salivary glands represent mucosaassociated lymphoid tissue located at the portal of entry and replication of EBV. Recently, the demonstration of the EBV/C3d receptor on cells from the stratified squamous epithelium of the oropharynx (Young et al., 1986; Talacko et al., 1991) , which also covers the tonsils, has lead to the current hypothesis that this epithelium plays an important role in EBV persistence and the pathogenesis of B cell tumours (Allday & Crawford, 1988) . In view of these findings, the observation of human palatine tonsils as a potential source of the EBVassociated lymphomas reported here is of particular importance.
Most of the human lymphoma-bearing hu-TMC-SCID mice in this study had antibodies against late EBV antigens. This finding contrasts with the recent observation by Rowe et al. (1991) , who did not detect antibodies to EBV VCA in hu-PBL-SCID mice at the time of tumour development. However, these authors investigated two of these mice longitudinally and found anti-VCA antibodies at stable titres up to 6 weeks after hu-PBL transfer. Since the tumours in hu-PBL-SCID mice evolved later than those in the hu-TMC-SCID mice, the difference might be related to the different periods of observation. Alternatively, the repertoire of engraftable B cells observed in SCID mice engrafted wth human cells may be limited (Saxon et al., 1991) . Such a limitation may have resulted in the paucity of anti-VCA antibodies in two of the tumour-bearing hu-TMC-SCID mice reported here. It is not clear whether the high anti-VCA antibody titres detected in hu-TMC-SCID mice with tumours in this study reflect baseline or antigen-boosted antibody production, a result of prior priming. Antigen-specific human antibody production upon antigen challenge has been reported in SCID mice engrafted with human cells (Mosier et al., 1988; Nadal et al., 1991 b) . High anti-VCA antibody titres in patients with EBV-associated lymphoproliferation have been attributed to continued virus activity (Harabuchi et al., 1990 ).
An observation of interest in our study was that six of the 10 mice with human tumours had detectable serum levels of human IL-6. Synthesis of IL-6 occurs in various cell types including endothelial cells, fibroblasts, osteoblasts, certain T cells and myeloma cells (Kawano et al., 1988; Hirano et al., 1990; Van Snick, 1990 ). IL-6 production has been detected in tonsils, but the cells involved have not yet been identified (Bosseloir et al., 1989) . IL-6 is a potent B cell-stimulating factor required for the growth of these ceils and their terminal differentiation into Ig-secreting plasma cells (Hirano et al., 1986; Muraguchi et al., 1988) . It can confer growth autonomy and tumorigenicity to B cells (Tohyama et al., 1990) , and enhance the growth of plasmacytomas in both humans and mice (Kawano et al., 1988; Klein et al., 1989; Zhang et al., 1989; Vink et al., 1990) . There is still controversy regarding whether the source of IL-6 in neoplasia is autocrine or paracrine (Kawano et al., 1988; Klein et al., 1989) . With respect to B cells infected with EBV, IL-6 has been shown to enhance virus-induced B cell proliferation and Ig production in vitro 30-to 50-fold (Tosato et al., 1988) , and to produce human B cell tumours in immunodeficient nude mice in vivo (Scala et al., 1990) . The results of our study suggest that IL-6 potentiates EBV-associated lymphogenesis. However, IL-6 does not appear to be a prerequisite for such virusinduced lymphoproliferation.
